BioPulse International Inc. will develop a multiple
tumor-specific cancer vaccines based on its dendritic cell cancer vaccine
technology. BioPulse expects to begin clinical trials of the tumor-specific
cancer vaccines outside the US in the first quarter, to be followed by
clinical trials inside the US. These new vaccines will potentially offer
additional alternatives to cancer patients.
Cancer vaccines that have been under investigation by BioPulse previously
utilized only patient-specific tumor antigens. This approach provides a
customized and specific vaccine product for each patient. The new
tumor-specific vaccines utilize a combination of tumor antigens designed to
target a class of tumors. This strategy potentially allows for a single
vaccine to be useful to a variety of patients that share a common tumor type.
"The significance of this development is that it offers the potential of
an off-the-shelf vaccine that can be available immediately to a cancer
patient," said Loran Swensen, president of BioPulse. "For some patients,
tumor-specific vaccines may be sufficient. In other cases, a combination of
tumor- and patient-specific cancer vaccines may be warranted."
Several biotech companies are researching cancer vaccines using
bio-engineered tumor antigens. The BioPulse tumor-specific cancer vaccine
technology is based instead on natural tumor antigens, consistent with the
BioPulse approach of utilizing the best that nature and biotechnology have to
offer. The company reported that pre-clinical studies have been promising.
Biopulse expects to begin clinical trials of the tumor-specific cancer
vaccines outside the united states in the first quarter of 2001, to be
followed by clinical trials inside the united states.